Factor V Arg506 → Gln mutation in patients with antiphospholipid antibodies

Lupus

Volumn 5, Issue 4, 1996, Pages 303-306

  Montaruli, B ^a   Borchiellini, A ^a   Tamponi, G ^c   Giorda, L ^c   Bessone, P ^c   Van Mourik, J A ^b   Voorberg, J ^b   Schinco, P C ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CENTRAL LABORATORY   (Netherlands)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

APA; Arterial thrombosis; Factor V; Venous thrombosis

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 5; PHOSPHOLIPID ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; LUPUS ANTICOAGULANT;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; PRIORITY JOURNAL; VEIN THROMBOSIS; AUTOIMMUNE DISEASE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; COMPARATIVE STUDY; DISEASE PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POINT MUTATION; POLYMERASE CHAIN REACTION; RISK FACTOR; THROMBOPHLEBITIS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL OCCLUSIVE DISEASES; AUTOIMMUNE DISEASES; DISEASE SUSCEPTIBILITY; DNA MUTATIONAL ANALYSIS; FACTOR V; FACTOR V DEFICIENCY; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; RISK FACTORS; THROMBOPHLEBITIS; THROMBOSIS;

EID: 0029658534     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500411     Document Type: Article

References (14)

1. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulant and other 'antiphospholipid' autoantibodies. Blood 1994; 84: 2854-2867.
2. Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995; 78: 1-31.
3. de Groot PG, Derksen RHWM. Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 1994; 3: 229-233.
4. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Thromb Haemost 1995; 74: 139-148.
5. Davies KA, Ireland H, Athanassiou P et al. Factor V Leiden mutation and venous thrombosis. Lancet 1995; 345: 132-133.
6. Dizon-Twomon D, Hutchinson C, Silver R et al. The factor V mutation which predisposes to thrombosis is not common in patients with antiphospholipid antibodies syndrome. Thromb Haemost 1995; 74: 1029-1031.
7. Bokarewa MI, Bremme K, Falk G et al. Studies on phospholipid antibodies, APC resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 3: 193-200.
8. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulant. SSC Subcommittee for the standardization of lupus anticoagulant. Thromb Haemost 1991; 65: 320-332.
9. Triplett DA. Laboratory diagnosis of lupus anticoagulants. Seminars in Thromb Haemost 1990; 16: 182-192.
10. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report: fifth international symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 46: 1-6.
11. 506 of factor V. Lancet 1994; 343: 1535-1536.
12. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
13. Hasselaar P, Derksen RHWM, Oosting JD et al. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by endothelial cells. Thromb Haemost 1989; 62: 654-660.
14. Derksen RHWM, Hasselaar P, Blokzijl L et al. Coagulation screen is more specific than anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheumatol Dis 1988; 47: 364-371.